Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of Silexan.

Kasper, Siegfried; Eckert, Anne; Möller, Hans-Jürgen; Volz, Hans-Peter; Seifritz, Erich

Kasper, Siegfried; Eckert, Anne; Möller, Hans-Jürgen; Volz, Hans-Peter; Seifritz, Erich.

Afiliação

Kasper S; Center of Brain Research, University of Vienna, Vienna, Austria.
Eckert A; Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland.
Möller HJ; Clinic and Policlinic for Psychiatry and Psychotherapy, Ludwig-Maximilian-University Munich, Munich, Germany.
Volz HP; Hospital for Psychiatry, Psychotherapy and Psychosomatic Medicine Schloss Werneck, Werneck, Germany.
Seifritz E; Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland.

Int J Psychiatry Clin Pract ; 27(3): 285-291, 2023 Sep.

Article em En | MEDLINE | ID: mdl-37021969

Assuntos

COVID-19; Óleos Voláteis; Humanos; Síndrome de COVID-19 Pós-Aguda; COVID-19/complicações; Óleos de Plantas; Óleos Voláteis/farmacologia

Palavras-chave

Silexan; anxiety; depressive symptoms; mixed psychiatric manifestations; post-COVID-19 syndrome; psychiatric symptoms

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Óleos Voláteis / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Int J Psychiatry Clin Pract Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Áustria

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google